DNA News and Research

RSS

DNA, or deoxyribonucleic acid, is the hereditary material in humans and almost all other organisms. Nearly every cell in a person’s body has the same DNA. Most DNA is located in the cell nucleus (where it is called nuclear DNA), but a small amount of DNA can also be found in the mitochondria (where it is called mitochondrial DNA or mtDNA).

Oxford Nanopore signs new agreement to strengthen University of Oxford collaboration

Oxford Nanopore Technologies Ltd is pleased to announce a new agreement to strengthen the Company's collaboration with the University of Oxford. The Company will fund research in the laboratories of Professor Hagan Bayley and will partner exclusively with the University to develop revolutionary products for molecular analysis from these new discoveries.

From Oxford Nanopore Technologies 15 Sep 2010

Norgen Biotek launches three novel kits for urine sampling

Norgen Biotek Corp, a privately held Canadian biotechnology company focusing principally on advancing a powerful proprietary technology for application in sample preparation for nucleic acid (DNA, RNA and microRNA) and protein purification, today announced the expansion of its basket of urine-based sample preparation products by launching 3 new urine concentration, preservation and isolation kits.

15 Sep 2010

MVI agrees to provide fund for evaluating Inovio's malaria DNA vaccine candidate in non-human primates

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the PATH Malaria Vaccine Initiative (MVI) has agreed to provide follow-on funding to continue evaluation and development of Inovio's malaria DNA vaccine candidate in non-human primates.

15 Sep 2010

TriLink signs licensing agreement to use CleanAmp dNTPs in Biofortuna's PCR kits

TriLink BioTechnologies, Inc. announced that it has signed a licensing agreement with Biofortuna Ltd. (Biofortuna) for use of CleanAmp dNTPs in Biofortuna's freeze dried in vitro diagnostic PCR kits.

15 Sep 2010

CytoGenix reports positive results of CYDBA507 avian influenza vaccine candidate

CytoGenix reports positive results of an animal study where mice were immunized with CYDBA507, CytoGenix avian influenza vaccine candidate, protected against lethal challenge with avian influenza virus.

15 Sep 2010

Notch1 protein impacts childhood leukemia progression: Study

A protein crucial for the immune response appears to be a key player in the progression of a devastating form of childhood leukemia called T-cell acute lymphoblastic leukemia (T-ALL). Suppressing the activity of the protein kills the leukemic cells, the study shows, opening a potential avenue to new drugs that could prevent progression of the disease.

14 Sep 2010

NHGRI announces fund to develop third generation DNA sequencing technologies

More than $18 million in grants to spur the development of a third generation of DNA sequencing technologies was announced today by the National Human Genome Research Institute (NHGRI). The new technologies will sequence a person's DNA quickly and cost-effectively so it routinely can be used by biomedical researchers and health care workers to improve the prevention, diagnosis and treatment of human disease.

14 Sep 2010

Researchers identify body's control switch system to eliminate damaged cells

St. Jude Children's Research Hospital scientists discovered a new mechanism cells use to maximize production of a key protein following DNA damage and demonstrated the potential of small molecules to regulate the process and protect healthy tissue.

14 Sep 2010

HFSA Meeting to discuss genomic diseases similarities in animals, humans

The 14th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) will feature a discussion on the similarities in genomic diseases between animals and humans, titled "Comparative Genomics and Human Disease,Some Recent Contributions from Zoos."

14 Sep 2010

Platinum and light together fight cancer

Researchers continue to search for cancer treatments that effectively destroy tumor cells while protecting surrounding healthy tissue and the body. One intriguing approach involves photoactivated drugs: an inactive precursor would be administered, then the diseased tissue could be irradiated to convert the drug into its cytotoxic form locally.

14 Sep 2010

Molecule microRNA-21 enhances growth and survival of existing lung cancer

A tiny molecule that spurs the progression of non-small-cell lung cancer could become a player in fighting the disease, say researchers at UT Southwestern Medical Center, who published a study on how the molecule behaves in mice in the Sept. 14 issue of Cancer Cell.

14 Sep 2010

$Cell Therapeutics to appeal FDA decision on pixantrone NDA for relapsed/refractory aggressive NHL$

Cell Therapeutics to appeal FDA decision on pixantrone NDA for relapsed/refractory aggressive NHL

Cell Therapeutics, Inc. today announced that it intends to appeal the U.S. Food and Drug Administration's previously disclosed decision regarding the pixantrone New Drug Application ("NDA") to treat patients with relapsed/refractory aggressive non-Hodgkin's lymphoma ("NHL").

14 Sep 2010

NIH awards QuantaLife $6 million to build platform for detecting MRSA infections

QuantaLife, a new life science tool company developing the third generation of PCR, has received an NIH grant totaling ~$6 million over 5 years for the development of rapid, cost-effective technology for detecting methicillin-resistant Staphylococcus aureus (MRSA) infections. The grant, from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the National Institutes of Health, will fund the project.

14 Sep 2010

Transgenomic expands EU distribution of SURVEYOR Scan K-RAS CE IVD mutation detection kit

Transgenomic, Inc. today announced that it completed the requirements for CE IVD labeling and has significantly expanded distribution of its SURVEYOR® Scan K-RAS mutation detection kit throughout most of the European Union. The SURVEYOR Scan K-RAS CE IVD kit is a member of Transgenomic's family of mutation detection kits, which features proprietary SURVEYOR endonuclease technology.

14 Sep 2010

AskBio enters patent license agreement with Pfizer for HCV therapy

Asklepios BioPharmaceutical, Inc., a privately-owned clinical-stage biotechnology company, announced today it has entered into a patent license agreement with Pfizer, Inc. granting Pfizer access to certain proprietary gene-delivery platform technologies developed by AskBio, for use in developing novel therapies for patients with Hepatitis C virus (HCV).

14 Sep 2010

Pharmacyclics reports $9.3 million increase in total revenue for 2010 fiscal year

Pharmacyclics, Inc. today reported financial results for its fiscal year and fourth quarter which ended June 30, 2010.

14 Sep 2010

Myopia and Glaucoma genes identified

In global studies of more than 40,000 people from countries around the world, including Australia, researchers have found the genes responsible for two of the most common eye disorders - short-sightedness or myopia and glaucoma. The scientists believe this could open new diagnostic and management options.

13 Sep 2010

Genomas awarded method patent for PhyzioGenomics Technology

Genomas®, a biomedical company advancing DNA-Guided Medicine, has been awarded US Patent 7,747,392, entitled Physiogenomic Method for Predicting Clinical Outcomes of Treatment in Patients by the US Patent and Trademark Office.

13 Sep 2010

Vical's TransVax CMV vaccine achieves key endpoints in Phase 2 trial in immunocompromised HCT recipients

Vical Incorporated announced today the achievement of key efficacy, immunogenicity and safety results in a Phase 2 trial, establishing its TransVax™ cytomegalovirus (CMV) vaccine as the first to provide evidence of protection in immunocompromised hematopoietic cell transplant (HCT) recipients, and defining a potential pathway for further development.

13 Sep 2010

Cyclacel reaches SPA agreement with FDA for sapacitabine Phase 3 trial in AML

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.

13 Sep 2010

DNA News and Research

Further Reading

Oxford Nanopore signs new agreement to strengthen University of Oxford collaboration

Norgen Biotek launches three novel kits for urine sampling

MVI agrees to provide fund for evaluating Inovio's malaria DNA vaccine candidate in non-human primates

TriLink signs licensing agreement to use CleanAmp dNTPs in Biofortuna's PCR kits

CytoGenix reports positive results of CYDBA507 avian influenza vaccine candidate

Notch1 protein impacts childhood leukemia progression: Study

NHGRI announces fund to develop third generation DNA sequencing technologies

Researchers identify body's control switch system to eliminate damaged cells

HFSA Meeting to discuss genomic diseases similarities in animals, humans

Platinum and light together fight cancer

Molecule microRNA-21 enhances growth and survival of existing lung cancer

Cell Therapeutics to appeal FDA decision on pixantrone NDA for relapsed/refractory aggressive NHL

NIH awards QuantaLife $6 million to build platform for detecting MRSA infections

Transgenomic expands EU distribution of SURVEYOR Scan K-RAS CE IVD mutation detection kit

AskBio enters patent license agreement with Pfizer for HCV therapy

Pharmacyclics reports $9.3 million increase in total revenue for 2010 fiscal year

Myopia and Glaucoma genes identified

Genomas awarded method patent for PhyzioGenomics Technology

Vical's TransVax CMV vaccine achieves key endpoints in Phase 2 trial in immunocompromised HCT recipients

Cyclacel reaches SPA agreement with FDA for sapacitabine Phase 3 trial in AML

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News